Rana JS, Boekholdt SM, Kastelein JJ, et al. Curr Atheroscler Rep. 2011. [Epub ahead of print]
Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges.
Sampson UK, Fazio S, Linton MF. Curr Atheroscler Rep. 2012;14:1-10.
AIM-HIGH Investigators, Boden WE, Probstfield JL, et al. N Engl J Med. 2011;365:2255-2267.
Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Cushman WC, Davis BR, Pressel SL, et al. J Clin Hypertens (Greenwich). 2012;14:20-31.
Evidence-based prediction of statin use with lipid-panel data from the National Health and Nutrition Examination Survey.
Gorevski E, Bian B, Kelton CM, et al. Value Health. 2012;15:32-38.
Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study.
Virani SS, Brautbar A, Davis BC, et al. Circulation. 2012;125:241-249.
Culver AL, Ockene IS, Balasubramanian R, et al. Arch Intern Med. 2012;172:144-152.
Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trials.
Morrone D, Weintraub WS, Toth PP, et al. Atherosclerosis. 2012. [Epub ahead of print]
Comparison of Lipid-Modifying Efficacy of Rosuvastatin Versus Atorvastatin in Patients With Acute Coronary Syndrome (from the LUNAR Study).
Pitt B, Loscalzo J, Monyak J, et al. Am J Cardiol. 2012. [Epub ahead of print]
Changes in fitness and fatness on the development of cardiovascular disease risk factors hypertension, metabolic syndrome, and hypercholesterolemia.
Lee DC, Sui X, Church TS, et al. J Am Coll Cardiol. 2012;59:665-672.